The Real-world Data (RWD) Market is projected to grow at a CAGR of 7.4% from 2022 to 2029 to reach $1.66 billion by 2029.
Real-world data (RWD) has become a powerful tool in the life sciences industry by pharmaceutical, biotechnology, & medical device companies; healthcare payers; healthcare providers; and other end users (academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies) to add value at every stage of the drug development lifecycle from understanding unmet healthcare needs and defining the patient journey to supporting regulatory submissions and post-market studies, offering value to payers, and defining market strategies.
Rapidly growing big data in healthcare, shift from volume to value-based care, and rising focus on personalized healthcare have positively impacted the RWD market. However, the lack of standardized methodologies to generate RWD poses a market challenge.
The Rising Adoption of Wearable Devices and Artificial Intelligence in RWD Creates Opportunities in the Market
The use of computers, mobile devices, wearables, and other biosensors to gather & store massive amounts of health-related data has rapidly accelerated. This data holds the potential to better design and conduct clinical trials & studies in the healthcare setting to answer questions previously thought infeasible. Additionally, with the development of sophisticated, new analytical capabilities, we can better analyze these data and apply the results of our analysis to medical product development and approval.
Real-world data generated from wearable devices & mobile apps and novel clinical trials are transforming the future of the healthcare industry. The role of wearable devices is also emerging in collecting real-world data. Wearable devices are clinically useful for better monitoring real-time, long-term, dynamic & pathological processes. These are convenient for managing chronic illnesses such as cardiovascular diseases, sleep disorders, and cognitive impairment. Recently, there has been a growing adoption of health and wellness devices to track fitness activities, sleeping habits, body temperature, and heart rate.
In the last few years, wearable device adoption has increased along with the growing adoption of healthcare apps. The wearables industry is constantly changing and continuously evolving. However, the wearables market is still growing and is currently dominated by health, wellness, and activity tracking devices. For instance, in March 2020, Fitbit Inc. (U.S.) launched Fitbit Charge 4, the most advanced health & fitness tracker with built-in GPS, active zone minutes, and sleep tools.
Artificial intelligence (AI), especially machine- and deep-learning (ML/DL) methods, have been increasingly used across many stages of the drug development process. Advancements in AI have also provided new strategies to analyze large and multidimensional RWD. AI’s ground-breaking leaps in protein structure identification and advances in regulations on the potential use of real-world evidence provide healthcare research organizations with access to real-world data to accelerate clinical trial processes. For instance, in 2021, Savana, a leader in Deep Real-world Evidence clinical research and BREATHE – The Health Data Research Hub for Respiratory Health partnered to further the use of EHR data for vital respiratory research.
-Market.webp "Real-world Data (RWD) Market")
Click here to: Get Free Sample Pages of this Report
Key Findings in the Global RWD Market Study
EMR/EHR/Clinical Data Generated Larger Proportion of Revenue Compared to Claims & Billing Data, Pharmacy Data, Product/Disease Registries Data, Genomics Data, and Other Datasets
In 2022, the EMR/EHR/clinical data segment is estimated to account for the largest market share of the RWD market owing to the significant amounts of data generated in hospitals, the increasing adoption of HER/EMR in hospitals, and the increased use of clinical data for RWE generation.
Market Access & Reimbursement/Coverage Decisions to Dominate the RWD Market
In 2022, the market access & reimbursement/coverage decisions segment is estimated to account for the largest share of the RWD market. The large market share of this segment is attributed to the increasing demand for real-world data to accelerate market access & reimbursement/coverage decisions, increasing investments by biopharmaceutical companies in R&D, and the growing inclination of regulatory bodies toward using real-world data studies.
Pharmaceutical & Medical Device Companies Segment to Register Largest Market Share of the RWD market by 2029
In 2022, the pharmaceutical & medical device companies segment is estimated to account for the largest market share of the RWD market. The large market share of this segment is attributed to the increasing importance of RWD in drug development & approvals, and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.
North America to Dominate the RWD Market
In 2022, North America is estimated to command the largest market share of the global RWD market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The rising burden of chronic diseases in the geriatric population, shift towards value-based care, growth of personalized healthcare, availability of electronic datasets, a well-developed healthcare industry, and rising big data in healthcare are some of the major factors expected to drive the growth of this regional segment during the forecast period. Additionally, rising R&D expenditure by biopharma companies, greater emphasis on early drug/device development & approvals, presence of major RWE players in the region, and implementation of the 21st Century Cures Act (December 2016) and FDA’s Framework for RWE (December 2018) in the U.S. are also stimulating the growth of this region.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past four years. The key players profiled in the global RWD market report are Anthem, Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).
Scope of the Report
RWD Market, by Source
RWD Market, by Application
RWD Market, by End User
RWD Market, by Geography
Key questions answered in the report:
The global RWD market covers the market size & forecasts of different real-world data solutions offered by key market players to support pharmaceutical, biotechnology, and medical device companies, healthcare payers, healthcare providers, and other end users in making key decisions related to market access & reimbursement/coverage decisions, drug development & approvals, post-market surveillance, medical device development & approvals. The RWD market report involves the value analysis of various segments and sub-segments of RWD providers at regional and country levels.
The RWD market is projected to reach $1.66 billion by 2029, at a CAGR of 7.4% during the forecast period.
Based on source, in 2022, the EMR/EHR/clinical data segment is estimated to account for the largest market share of the RWD market owing to the significant amounts of data generated in hospitals, the increasing adoption of EHR/EMR in hospitals, and the increased use of clinical data for RWE generation. EHRs are the most commonly used form of healthcare database, playing an increasingly vital role in collecting and generating actionable information at the FDA. The federal agency is focused on making real-world data (RWD) available for clinical studies as a strategic priority and intends to issue guidance on supporting “more accessible clinical trials” through a decentralized approach. Such initiatives would propel the adoption of EHR data for real-world data generation during the forecast period.
Based on application, the drug development & approvals segment is expected to show the fastest growth rate during the forecast period. Factors attributing to the growth of this segment are increasing demand for real-world data to enhance drug discovery and development and increasing investments by biopharmaceutical companies in R&D. In the field of drug development, quality-of-life metrics, and Patient-Reported Outcome Measures (PROMs) are now becoming common clinical trial elements. The real-world data is regularly utilized to inform aspects of drug development. Adopting AI in drug development & approval processes is also driving the demand for RWD. AI integrated RWD studies are conducted in various stages of the drug development process, such as designing clinical trials, modeling & forecasting patient enrichment and recruitment using multiple RWD sources, selecting investigator site, patient monitoring & managing and medication adherence & retention, market access, and post-market surveillance
Rapidly growing data in healthcare, shift from volume to value-based care, and rising focus on personalized healthcare have positively impacted the RWD market. Additionally, emerging markets and the roles of wearable devices, social media, and AI in the RWD generation are some factors expected to offer growth opportunities for players operating in the RWD market.
Key companies operating in the global RWD market are Anthem, Inc. (U.S.), IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).
Emerging economies like Japan and China are projected to offer significant growth opportunities for the companies in the RWD market. Growing demand for data defining the value and effectiveness of medicines by payers, growing demand for RWD studies in drug R&D, and increasing government interest in using real-world studies for regulatory decision-making are the factors that will offer significant growth opportunities in this region.
This report provides pre & post COVID-19 market estimates.
List of Tables
Table 1 Global Real-world Data Market Drivers: Impact Analysis (2022–2029)
Table 2 Total Cost Per Study, by Phase and Therapeutic Area (USD Million)
Table 3 Number of Persons Aged 65 Years or Above, by Region (2019 Vs. 2050)
Table 4 Sources of Healthcare Data
Table 5 Global Real-world Data Market Restraints: Impact Analysis (2022–2029)
Table 6 Real-world Data in Latin American Countries
Table 7 Observed Indicative Prices of Real-world Data by Type (USD Per Patient Record)
Table 8 Global Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 9 Global Real-world Data Market Size for EMR/EHR/Clinical Data, by Country/Region, 2020–2029 (USD Million)
Table 10 Global Real-world Data Market Size for Claims & Billing Data, by Country/Region, 2020–2029 (USD Million)
Table 11 Global Real-world Data Market Size for Pharmacy Data, by Country/Region, 2020–2029 (USD Million)
Table 12 Global Real-world Data Market Size for Product/Disease Registries Data, by Country/Region, 2020–2029 (USD Million)
Table 13 Global Real-world Data Market Size for Genomics Data, by Country/Region, 2020–2029 (USD Million)
Table 14 Global Real-world Data Market Size for Other Sources, by Country/Region, 2020–2029 (USD Million)
Table 15 Global Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 16 Global Real-world Data Market Size for Access & Reimbursement/Coverage Decision, by Country/Region, 2020–2029 (USD Million)
Table 17 Global Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 18 Global Real-world Data Market Size for Drug Development & Approvals, by Country/Region, 2020–2029 (USD Million)
Table 19 Oncology: Drugs in the R&D Pipeline
Table 20 Global Drug Development & Approvals Market Size for Oncology, by Country/Region, 2020–2029 (USD Million)
Table 21 Neurology: Drugs in the R&D Pipeline
Table 22 Global Drug Development & Approvals Market Size for Neurology, by Country/Region, 2020–2029 (USD Million)
Table 23 Immunology: Drugs in the R&D Pipeline
Table 24 Global Drug Development & Approvals Market Size for Immunology, by Country/Region, 2020–2029 (USD Million)
Table 25 Medical Costs Associated With Cardiovascular Diseases (2010–2030) (USD Billion)
Table 26 Cardiovascular Diseases: Drugs in the R&D Pipeline
Table 27 Global Drug Development & Approvals Market Size for Cardiovascular Diseases, by Country/Region, 2020–2029 (USD Million)
Table 28 Other Therapeutic Areas: Drugs in the R&D Pipeline
Table 29 Global Drug Development & Approvals Market Size for Other Therapeutic Areas, by Country/Region, 2020–2029 (USD Million)
Table 30 Global Real-world Data Market Size for Medical Device Development & Approvals, by Country/Region, 2020–2029 (USD Million)
Table 31 Global Real-world Data Market Size for Post-market Surveillance, by Country/ Region, 2020–2029 (USD Million)
Table 32 Global Real-world Data Market Size for Clinical & Regulatory Decision-Making, by Country/Region, 2020–2029 (USD Million)
Table 33 Global Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 34 Global Real-world Data Market Size for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country/Region, 2020–2029(USD Million)
Table 35 Global Real-world Data Market Size for Healthcare Payers, by Country/Region, 2020–2029 (USD Million)
Table 36 Global Real-world Data Market Size for Healthcare Providers, by Country/Region, 2020–2029 (USD Million)
Table 37 Global Real-world Data Market Size for Other End Users, by Country/Region, 2020–2029 (USD Million)
Table 38 Global Real-world Data Market Size, by Country/Region, 2020–2029 (USD Million)
Table 39 North America: Real-world Data Market Size, by Country, 2020–2029 (USD Million)
Table 40 North America: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 41 North America: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 42 North America: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 43 North America: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 44 U.S.: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 45 U.S.: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 46 U.S.: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 47 U.S.: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 48 Number of Active Clinical Trials in Canada, by Condition (2020)
Table 49 Canada: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 50 Canada: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 51 Canada: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 52 Canada: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 53 Europe: Real-world Data Market Size, by Country/Region, 2020–2029 (USD Million)
Table 54 Europe: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 55 Europe: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 56 Europe: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 57 Europe: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 58 U.K.: Conferences and Workshops on Real-world Data Solutions
Table 59 U.K.: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 60 U.K.: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 61 U.K.: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 62 U.K.: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 63 Conferences, Symposia, and Workshops in Germany
Table 64 Germany: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 65 Germany: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 66 Germany: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 67 Germany: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 68 France: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 69 France: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 70 France: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 71 France: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 72 Italy: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 73 Italy: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 74 Italy: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 75 Italy: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 76 Spain: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 77 Spain: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 78 Spain: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 79 Spain: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 80 Rest of Europe: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 81 Rest of Europe: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 82 Rest of Europe: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 83 Rest of Europe: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 84 Asia-Pacific: Real-world Data Market Size, by Country/Region, 2020–2029 (USD Million)
Table 85 Asia-Pacific: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 86 Asia-Pacific: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 87 Asia-Pacific: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 88 Asia-Pacific: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 89 Japan: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 90 Japan: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 91 Japan: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 92 Japan: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 93 China: Diversified Real-world Data Sources
Table 94 China: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 95 China: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 96 China: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 97 China: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 98 India: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 99 India: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 100 India: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 101 India: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 102 South Korea: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 103 South Korea: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 104 South Korea: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 105 South Korea: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 106 Taiwan: Rwe Sources
Table 107 Taiwan: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 108 Taiwan: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 109 Taiwan: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 110 Taiwan: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 111 Singapore: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 112 Singapore: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 113 Singapore: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 114 Singapore: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 115 Estimated Number of New Cancer Cases From 2020 To 2030
Table 116 Rest of Asia-Pacific: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 117 Rest of Asia-Pacific: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 118 Rest of Asia-Pacific: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 119 Rest of Asia-Pacific: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 120 Latin America: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 121 Latin America: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 122 Latin America: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 123 Latin America: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 124 Middle East & Africa: Real-world Data Market Size, by Source, 2020–2029 (USD Million)
Table 125 Middle East & Africa: Real-world Data Market Size, by Application, 2020–2029 (USD Million)
Table 126 Middle East & Africa: Real-world Data Market Size for Drug Development & Approvals, by Therapeutic Area, 2020–2029 (USD Million)
Table 127 Middle East & Africa: Real-world Data Market Size, by End User, 2020–2029 (USD Million)
Table 128 Recent Developments, by Company, 2018–2021
List of Figures
Figure 1 Key Stakeholders
Figure 2 Research Process
Figure 3 Key Secondary Sources
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 7 Market Size Estimation
Figure 8 Global Real-world Data Market, by Source, 2022 Vs. 2029 (USD Million)
Figure 9 Global Real-world Data Market, by Application, 2022 Vs. 2029 (USD Million)
Figure 10 Global Real-world Data Market, by End User, 2022 Vs. 2029 (USD Million)
Figure 11 Global Real-world Data Market, by Geography
Figure 12 Market Dynamics
Figure 13 Percentage of Personalized Medicines Approved (2015–2020)
Figure 14 U.S.: Number of People With Chronic Conditions (2000–2030)
Figure 15 Asia-Pacific: Percent Share of Global Clinical Trial Activities (2012–2020)
Figure 16 Global Real-world Data Market Size, by Source, 2022 Vs. 2029 (USD Million)
Figure 17 U.S.: Number of E-Prescriptions, 2013–2020 (In Billion)
Figure 18 Global Real-world Data Market Size, by Application, 2022 Vs. 2029 (USD Million)
Figure 19 Estimated Number of New Cancer Cases, by Region, 2020–2040 (In Million)
Figure 20 Global Real-world Data Market Size, by End User, 2022 Vs. 2029 (USD Million)
Figure 21 Pharmaceutical R&D Spending, 2012–2026 (USD Billion)
Figure 22 Global Real-world Data Market Size, by Region, 2022 Vs. 2029 (USD Million)
Figure 23 North America: Real-world Data Market Snapshot
Figure 24 Number of Novel Drugs Approved by the CDER (2010–2021)
Figure 25 Europe: Real-world Data Market Snapshot
Figure 26 Germany: Pharmaceutical R&D Expenditure, 2016–2020 (USD Million)
Figure 27 France: Share of the Population Aged 65 Years & Above (2010–2020)
Figure 28 Italy: Share of the Population Aged 65 Years and Above (2015–2020)
Figure 29 Spain: Pharmaceutical R&D Expenditure, 2016–2020 (USD Million)
Figure 30 Pharmaceutical R&D Expenditure in European Countries, 2016–2020 (USD Million)
Figure 31 Asia-Pacific: Real-world Data Market Snapshot
Figure 32 Japan: Number of People Below 65 Years of Age (2000–2050)
Figure 33 Key Growth Strategies Adopted by Leading Players (2018–2022)
Figure 34 Real-world Data Market: Competitive Benchmarking, by Geography
Figure 35 Market Share Analysis: Real-world Data Industry (2021)
Figure 36 Financial Overview (2019–2021): IQVIA Holdings Inc.
Figure 37 Financial Overview (2018–2020): PPD Inc.
Figure 38 Financial Overview (2019–2021): ICON plc
Figure 39 Financial Overview (2019–2021): UnitedHealth Group Incorporated
Figure 40 Financial Overview (2019–2021): Oracle Corporation
Figure 41 Financial Overview (2020–2021): SAS Institute Inc.
Figure 42 Financial Overview (2019–2021): Elevance Health, Inc.
Figure 43 Financial Overview (2019–2021): Clinigen Group plc
Figure 44 Financial Overview (2019–2021): Cognizant Technology Solutions Corporation
Figure 45 Financial Overview (2019–2022): PerkinElmer, Inc.
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Feb-2023
Published Date: Jan-2023
Published Date: Oct-2022
Published Date: Jul-2022
Published Date: Jul-2022
